ORXs Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 30.95 |
| 52 Week High | SEK 33.24 |
| 52 Week Low | SEK 18.68 |
| Beta | 0.93 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -53.25% |
| 5 Year Change | -30.76% |
| Change since IPO | -77.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORXs | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | 1.0% |
| 1Y | n/a | -3.2% | 6.3% |
Return vs Industry: Insufficient data to determine how ORXs performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ORXs performed against the UK Market.
Price Volatility
| ORXs volatility | |
|---|---|
| ORXs Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ORXs has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ORXs's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 126 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company’s development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain.
Orexo AB (publ) Fundamentals Summary
| ORXs fundamental statistics | |
|---|---|
| Market cap | SEK 635.80m |
| Earnings (TTM) | -SEK 151.70m |
| Revenue (TTM) | SEK 612.30m |
1.0x
P/S Ratio-4.2x
P/E RatioIs ORXs overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORXs income statement (TTM) | |
|---|---|
| Revenue | SEK 612.30m |
| Cost of Revenue | SEK 97.00m |
| Gross Profit | SEK 515.30m |
| Other Expenses | SEK 667.00m |
| Earnings | -SEK 151.70m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Jan 26, 2023
| Earnings per share (EPS) | -4.41 |
| Gross Margin | 84.16% |
| Net Profit Margin | -24.78% |
| Debt/Equity Ratio | 165.6% |
How did ORXs perform over the long term?
See historical performance and comparison